FDA ? Alternative Strategies in Dealing with the Agency to Develop and Gain Approval of Drugs and Medical Devices
Website https://compliance2go.com/product/?pid=CP2014-405 |
Category Biotechnology , Medical Device , Pharmaceutical
Deadline: January 15, 2029 | Date: January 15, 2029
Venue/Country: Houston, U.S.A
Updated: 2014-12-09 19:09:38 (GMT+9)
Call For Papers - CFPDESCRIPTIONWhy you should attendExecutives (VPs, Directors, Managers) and other professionals involved in developing and executing the strategies to secure approval/clearance of FDA-regulated drugs, biologics, and medical devices and diagnostics. In particular, professionals from these functional arenas:Regulatory, Research & Development, Compliance, Quality Assurance, Medical Affairs, Clinical Affairs, Clinical Operations, LegalDescription of the topicIn tackling the challenge of developing a drug or device product for FDA approval, a common assumption is that the effort will take years and cost the budget of a small city. And, then, when you file at FDA, you worry that you will have to wait forever for a decision. While there is some truth in that hyperbole, the reality is that there are a number of programs available at FDA that are designed to speed the development and approval process. In this webinar, we will explore those mechanisms for both drug (and biologic) and device (incuding diagnotics) products. Ranging from the new “breakthrough drug” provisions of the 2012 Food & Drug Administration Safety and Innovation Act (FDASIA) to the protocol assistance requirements of the 1983 Orphan Drug Act to the Special 510(k) process, we will review how to qualify for these programs, their benefits, and their burdens, all with aim of helping you, where possible, get your product to the market faster while still satisfying the legal requirements for approval.Areas Covered In the Sem
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.